To evaluate the accuracy of a magnetic resonance imaging (MRI)-based Likert scoring system in the detection of clinically significant prostate cancer (CSPC), using MRI/ ultrasonography (US) image-fusion targeted biopsy (FTB) as a reference standard.
Introduction
Compared with other imaging methods, MRI provides the best visualization of the prostate. Advances in MRI, such as the multiparametric (mp) approach, show promise for improved detection and characterization of prostate cancer. Furthermore, recent evidence suggests that mpMRI may better visualize clinically significant prostate cancer (CSPC) [1] . One major impediment to the promotion of mpMRI of the prostate, however, is a lack of standardization in the expression of results [2] . MpMRI data need to be presented to clinical colleagues in a simple but reliable standardized way, preferably using a structured reporting scheme [3] . Although a five-point Likert scoring system and the Prostate Imaging-Reporting and Data System (PI-RADS) are often used to evaluate mpMRI of the prostate, there is still controversy over the best way to report results [3, 4] . In addition, the ability to interpret MRI of the prostate is a critical clinical problem, and may depend on the radiologist's level of experience in this area.
Recently, increasing evidence supports the use of MRI/ ultrasonography (US) image-fusion targeted biopsy (FTB) to improve the detection of CSPC, while limiting detection of indolent cancers compared with conventional systematic random biopsy [5] [6] [7] .
Data on the association between all Likert scores (1) (2) (3) (4) (5) and the presence of CSPC and the use of MRI/US FTB to validate these scores, however, are lacking. The aim of the present study, therefore, was to evaluate the diagnostic accuracy of a five-point Likert scoring system, rated by radiologists with varying levels of experience in the detection of prostate cancer using MRI/US FTB as a reference standard, and to determine the potential ability of mpMRI to identify CSPC.
Patients and Methods
After obtaining institutional review board approval, we retrospectively reviewed 762 patients who underwent mpMRI of the prostate and subsequent MRI/US FTB at Chesapeake Urology Associates between October 2012 and August 2015. We excluded patients in whom MRI did not identify any visible lesions and patients who had received any previous treatments for prostate cancer. We also excluded patients whose MRI was interpreted by novice radiologists who had only minimal experience of prostate MRI (<20 cases) and patients whose biopsies were performed by novice urologists who had only minimal experience of MRI/US FTB (<20 cases) during the study period. A final total of 1218 MRIdetected lesions in 629 patients were included in this study (Fig. 1) .
The mpMRI was performed using a 3-Tesla magnetic field strength and a pelvic phased-array coil. T1-weighted, T2-weighted, diffusion-weighted and dynamic gadolinium contrast-enhanced imaging sequences, including the calculation of apparent diffusion coefficient maps, were acquired. Each MRI scan was independently interpreted by one of eight radiologists with varying levels of experience of mpMRI of the prostate in the clinical practice setting and who was not blinded to the clinical context. Each lesion was assigned a five-point Likert scale score (Table 1) [4] by the interpreting radiologist and all lesions with Likert scores 1-5 were defined as targets for MRI/US FTB. For detailed analysis, radiologists were grouped into experienced (three radiologists who had independently read >80 mpMRIs of the prostate during the study period) and less experienced radiologists (three radiologists who had independently read <50 mpMRIs).
Standard random biopsy was performed with the conventional systematic 10-12 cores per patient and targeted biopsy was performed with at least one core per lesion (all lesions with Likert scores 1-5) under general or local anaesthesia. Prostate biopsy for each patient was independently performed by one of four urologists with varying levels of experience of MRI/US FTB throughout the study period. Three-dimensional volume data of mpMRI and real-time TRUS images were visualized on the screen of a computer workstation (UroStation; Koelis, Grenoble, France) and used for MRI/US FTB [8] . Urologists were grouped into experienced urologists (two urologists who had performed MRI/US FTB independently in >120 cases during the study period) and less experienced urologists.
The definition of CSPC was set at Gleason score ≥3+4.
Statistical analyses were performed using SPSS Statistics version 23 (IBM Corporation, Armonk, NY, USA) software. P values <0.05 were taken to indicate statistical significance.
Results
Patient characteristics are shown in Table 2 . In 629 patients, the median age was 64.0 years, pre-biopsy PSA level was 6.97 ng/mL and estimated prostate volume was 52.2 mL. The median number of lesions on MRI was 2.0 per patient. The study population included the spectrum of men offered prostate biopsy, including: (i) biopsy-na€ ıve men with a clinical suspicion of prostate cancer based on elevated PSA level and/or abnormal DRE (n = 83, 13.2%); (ii) men with Of 1218 MRI-detected lesions, 48% (n = 581) were rated as Likert 1-2 (low suspicion), 35% (n = 428) were Likert 3 (equivocal suspicion) and 17% (n = 209) were Likert 4-5 (high suspicion; Fig. 2 ).
According to the five-point Likert system of grading from 1 to 5, overall cancer detection rates were 12%, 13%, 22%, 50% and 59% (Fig. 3A) , and CSPC detection rates were 4%, 4%, 12%, 33% and 48% ( Fig. 3B ), respectively. The 5-point scale showed strong positive correlation with overall cancer detection rate (r = 0.949, P = 0.05) and CSPC detection rate (r = 0.944, P = 0.05).
In addition, for Likert scores 1-5, the proportions of clinically insignificant cancer cores in all cancer positive cores were 66.7%, 74.1%, 46.8%, 34.6% and 19.4%, respectively (P < 0.001). Thus, the five-point Likert scale showed a strong negative correlation with the proportion of clinically insignificant cancers (r = À0.941, P = 0.05).
Comparison between Likert 4-5 (high suspicion) and Likert 3 lesions (equivocal suspicion) showed that the targeted biopsies from Likert 4-5 lesions yielded a higher overall cancer detection rate (55% vs 22%; P < 0.001) and CSPC detection rate (40% vs 12%; P < 0.001; Table 3 ).
A significant association between the radiologists' experience of prostate MRI and the detection rates of overall cancer and CSPC was identified in Likert 4-5 lesions. Comparison between the three more experienced radiologists in mpMRI of the prostate and the three less experienced radiologists showed significant differences in the overall cancer detection rates (63% vs 35%; P = 0.001) and CSPC detection rates (47% vs 29%; P = 0.027; Table 4 ). By contrast, no significant association between the urologists' experience of MRI/US FTB and the detection rates of overall cancer and CSPC was identified (Table 5) .
Finally, we compared conventional random biopsy with MRI/ US FTB (Table 6) . A higher proportion of cores was positive for any cancer using MRI/US FTB than random biopsy (25.6% vs 8.5%; P < 0.001). With regard to the proportion of clinically insignificant cancer cores in all cancer-positive cores, there was a significant difference between random biopsy and MRI/US FTB (48.3% vs 31.9%; P < 0.001). The median cancer core length with MRI/US FTB was significantly greater than that of random biopsy (5.0 vs 2.0 mm; P < 0.001). A higher proportion of patients were positive for CSPC using MRI/US FTB than random biopsy (20.7% vs 14.9%; P = 0.009). Moreover, random biopsy missed CSPC in 66 of 629 patients (10.5%), while MRI/US FTB missed it in only 1.6% (n = 10; P < 0.001).
Discussion
To the best of our knowledge, the present study is the first to show that radiologists' experience levels in prostate MRI interpretation using a Likert scale affected the detection rate of CSPC in transrectal MRI/US FTB. We used the number of cases in which each radiologist interpreted and reported mpMRI of the prostate during the study period as an indicator of the experience level for current mpMRI of the prostate. We recognize the importance of the evolving role of and rapid progress in MRI methodologies in the assessment of prostate cancer. We believe therefore that actual experience during the study period is more important than previous lifetime experience and strongly reflects radiologists' ability to adjust to new advances in MRI technology and to learn new improved skills in the interpretation of current mpMRI.
Recently, Gaziev et al. [9] reported the accuracy of mpMRI during the learning curve of radiologists using transperineal MRI/US FTB for validation. The cohorts were divided into groups representing five consecutive time intervals in the study. Overall cancer detection rates for Likert 4-5 lesions were 31.5% in the first cohort and 70.5% in the final cohort. In the present study, the overall cancer detection rates for Likert 4-5 lesions were 34.7% for less experienced radiologists and 62.7% for more experienced radiologists (P = 0.001). These are similar findings to those of the previous paper, although direct comparison is difficult because in the former study a different platform for image-fusion and a transperineal approach were used.
To enhance the detection of CSPC using MRI/US FTB, proper interpretation of mpMRI is essential and standardization, training and education in mpMRI prostate interpretation are important [10] . It was recently reported that the current PI-RADS version 2 may simplify and standardize the terminology and content of radiology reports, and also educate radiologists on prostate MRI reporting and reduce variability in imaging interpretation [11] . In addition, histopathological feedback to radiologists from urologists or pathologists may help to standardize and improve interpretation of mpMRI [12] .
The PREDICT (Prostate Diagnostic Imaging Consensus Meeting) panel recommended the use of a five-point Likert scale to express the results of mpMRI of the prostate [2] , whereas the European Society of Urogenital Radiology (ESUR) proposed the use of PI-RADS scoring [3] . Noticeably the Likert scale approach does not recommend fixed criteria for interpretation, yet has been found to perform better than PI-RADS for the detection of prostate cancer. Although the five-point Likert scale and PI-RADS scoring are well-known reporting systems for prostate MRI, there is still controversy over the best way to report results [11] . Rosenkrantz et al. [13] reported that diagnostic accuracy was similar for the PI-RADS version 1 and Likert scales in the peripheral zone, but was somewhat higher for the Likert scale than for the PI-RADS version 1 scale in the transition zone. By contrast, Roethke et al. [14] reported that the aggregated PI-RADS version 1 score was more valid than the Likert score.
In the present study, similarly to other reports [15] , the fivepoint Likert scale strongly correlated with overall cancer detection rate (r = 0.949) and CSPC detection rate (r = 0.944). Scores indicating higher suspicion (Likert 4-5) on MRI correlated strongly with a higher likelihood of overall cancer (55%) and CSPC (40%). Thus, targeted biopsy should be considered for the Likert 4-5 lesions. By contrast, scores indicating lower suspicion (Likert 1-2) on MRI may be useful in predicting a low likelihood of high grade cancer, so targeted biopsy could potentially be avoided. Likert score 3 represents equivocal suspicion and lesions need to be distinguished by further investigation.
By contrast, there was no significant difference in the detection rates of overall cancer and CSPC among urologists with different levels of experience for MRI/US FTB in the present study. These findings may be partly attributable to the software-based coregistration tool (the UroStation), which may have reduced issues of operator experience with visual targeting [8, 16] .
A major concern related to prostate cancer screening and early detection is over-diagnosis and over-treatment of indolent disease [17] . Strategies to reduce over-diagnosis are necessary, as are strategies to differentiate indolent from aggressive tumours. In other words, an ideal biopsy strategy to identify men with prostate cancer would be detection of only CSPC and minimization of insignificant cancer detection and consequent over-treatment.
The potential of mpMRI and subsequent MRI/US FTB for improved detection of CSPC and reduction in unnecessary biopsies of insignificant or absent prostate cancer may be promising, but is still being explored [5, 16, 18] . The present study showed that MRI/US FTB identified more CSPCs with many fewer biopsy cores compared with conventional random biopsy. A recent systematic review reported that MRI/US FTB identified CSPCs (median 9.1%) that were missed by standard random biopsy alone [19] . In the present study, MRI/US FTB found 66 patients (10.5%) with CSPC that was missed by random biopsy alone.
Although the detection rate has varied among previous studies, it was reported that the absolute difference in CSPC detection rate between MRI/US FTB and standard random biopsy was a median (range) of 6.8% (0.9-41.4%) [19] , and in the present study it was 5.8%. Moreover, the median cancer core length of positive MRI/US FTB-detected lesions was 2.5 times greater than that of random biopsies (5 vs 2 mm). In addition, we have recently reported that MRI/US FTB allowed accurate identification of the index lesion, which was defined as a lesion with the highest Gleason score or the largest volume or extraprostatic extension [20] .
These results imply that mpMRI and subsequent MRI/US FTB efficiently differentiate aggressive from indolent cancers, and reduce over-diagnosis and over-treatment of indolent cancers. This procedure may also become a useful tool for precise cancer mapping in focal therapy of prostate cancer.
The present study has some limitations. First, analysis was retrospective and the study population was heterogeneous, comprising biopsy-na€ ıve men, men with a previous negative biopsy and men with a previous positive biopsy. There is therefore the potential for selection bias. The main objective of the present study, however, was to evaluate the accuracy of the Likert scale itself scored by radiologists regardless of the reason for biopsy.
Second, our reference standard was a biopsy rather than a final prostatectomy specimen, so we cannot completely validate our scoring accuracy and determine the actual significance of a negative biopsy. In studies where wholemount radical prostatectomy has been used as the reference Third, our analysis excluded patients without any visible lesions on MRI, so we cannot assess the detection of CSPC in such patients. Fourth, the definition we used to indicate CSPC is open to debate because no universally accepted definition exists. We therefore performed a second analysis using another definition of CSPC (Gleason score ≥4+3 or a maximum cancer core length ≥6 mm), which was used in the PROMIS study [21] . In the second analysis, for the Likert system grades 1-5, CSPC detection rates were 3.4%, 3.7%, 9.1%, 33.7% and 42.9%, respectively (r = 0.934, P = 0.05). These results were very similar to our first analysis.
Lastly, the extra costs and efforts associated with mpMRI and MRI/US FTB should be further investigated with consideration given to possible cost savings resulting from reductions in repeat biopsies.
In conclusion, the overall cancer detection rates and rates of CSPC detection strongly correlated with a five-point Likert scale. Between radiologists with more and less experience in interpreting mpMRI of the prostate, there were significant differences in these cancer detection rates. Further investigations and efforts are necessary to develop a better-standardized reporting system and improve the education of radiologists in prostate mpMRI interpretation, including feedback to them from urologists and pathologists. We also showed that mpMRI of the prostate and subsequent MRI/US FTB resulted in better detection of CSPC than conventional random biopsy.
